Holen Sie sich die Stockscreener-App
42.94
2.67%
-1.18
Schlusskurs vom Vortag:
$44.12
Offen:
$44.53
24-Stunden-Volumen:
1.67M
Relative Volume:
0.61
Marktkapitalisierung:
$7.14B
Einnahmen:
$1.06B
Nettoeinkommen (Verlust:
$-326.58M
KGV:
-20.43
EPS:
-2.1022
Netto-Cashflow:
$-977.73M
1W Leistung:
-5.17%
1M Leistung:
-4.24%
6M Leistung:
-42.94%
1J Leistung:
-41.23%
1-Tages-Spanne:
$42.80
$44.65
1-Wochen-Bereich:
$42.08
$45.45
52-Wochen-Spanne:
$42.08
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
42.94 | 7.14B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-15 | Fortgesetzt | UBS | Buy |
| 2026-08-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2026-07-16 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-05-19 | Eingeleitet | Citigroup | Buy |
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-04-10 | Fortgesetzt | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Ionis Pharmaceuticals, Inc. (IONS) Stock Price, News, Quote & History - Yahoo! Finance Canada
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - Zacks Investment Research
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal - Zacks Investment Research
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Liquidia Corporation (LQDA) Stock Price & News - Syfe
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - The Motley Fool
Ionis Pharmaceuticals (NasdaqGS:IONS) Stock Forecast & Analyst Predictions - Simply Wall Street
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs - Zacks Investment Research
A kidney disease can progress to kidney failure in up to half of patients within 20 years. Ionis' drug met its trial goal. - Stock Titan
A rare genetic disease drug trial met its main goal. Otsuka plans FDA talks. - Stock Titan
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years – Retail Calls It ‘Opportunity Of A Lifetime’ - Stocktwits
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax Bio - Barchart.com
Ionis Has Its First Neurology Launch, But Can Zanvastro Justify Its $285,000 Price? - Yahoo Finance
Precision Trading with Ionis Pharmaceuticals Inc. (IONS) Risk Zones - Stock Traders Daily
Rx Rundown: GSK, Novartis, Ionis Pharmaceuticals and more - Medical Marketing and Media
Ethan Weiss: Two Trial Flops End the "Genetics Is Undefeated" Era in Heart Drugs - finance.biggo.com
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Ionis at Wells Fargo healthcare conference: launches offset setbacks - investing.com
Ionis at Wells Fargo healthcare conference: launches offset setbacks By Investing.com - Investing.com Canada
IONS: Strategic approvals and strong launches drive growth, with pipeline poised for further milestones - TradingView
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. - Yahoo Finance
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? - Zacks Investment Research
IONS Maintained by Barclays -- Price Target Lowered to $85.00 - GuruFocus
Ionis Pharmaceuticals (IONS) Institutional Ownership 2026 $IONS - MarketBeat
BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $91 - Moomoo
Raymond James cuts Ionis Pharmaceuticals price target on trial miss - Investing.com
Raymond James cuts Ionis Pharmaceuticals price target on trial miss By Investing.com - Investing.com Canada
Raymond James cuts Ionis Pharmaceuticals price target on trial miss By Investing.com - Investing.com India
Raymond James Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $84 - Moomoo
Retatrutide clears BLA bar while Wainua stumbles in busy July for trials - BioWorld News
IONS Maintained by Goldman Sachs -- Price Target Lowered to $56 - GuruFocus
BMO cuts Ionis Pharmaceuticals stock price target on drug failure By Investing.com - Investing.com Canada
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha
BMO cuts Ionis Pharmaceuticals stock price target on drug failure By Investing.com - Investing.com UK
Ionis Pharmaceuticals gets $85 price target des... - Pluang
H.C. Wainwright cuts Ionis stock price target to $100 on pelacarsen removal - Investing.com
Canaccord cuts Ionis stock price target to $85 on pelacarsen trial miss - Investing.com
H.C. Wainwright cuts Ionis stock price target to $100 on pelacarsen removal - Investing.com Canada
Canaccord cuts Ionis stock price target to $85 on pelacarsen trial miss - Investing.com Canada
Needham reiterates Ionis stock rating after trial failure By Investing.com - Investing.com India
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss - TipRanks
IONS Maintained by HC Wainwright & Co. -- Price Target Lowered to $100 - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint - Yahoo Finance
Why is Ionis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com India
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander DiseaseSlideshow (NASDAQ:IONS) 2026-09-07 - Seeking Alpha
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment - Yahoo
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal - Zacks Investment Research
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ionis Pharmaceuticals Inc-Aktie (IONS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hayden Michael R | Director |
Jul 31 '26 |
Buy |
51.60 |
5,000 |
258,000 |
24,000 |
| Hayden Michael R | Director |
Jul 30 '26 |
Buy |
53.38 |
15,000 |
800,700 |
19,000 |
| BERTHELSEN SPENCER R | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
5,220 |
0 |
161,233 |
| HERMAN JOAN E | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
5,220 |
0 |
51,306 |
| Diaz Allene M. | Director |
Jul 07 '26 |
Sale |
85.42 |
10,111 |
863,637 |
3,811 |
| Kordasiewicz Holly B. | EVP, Chief Development Officer |
Jul 07 '26 |
Sale |
84.30 |
362 |
30,517 |
22,096 |
| Diaz Allene M. | Director |
Jul 07 '26 |
Proposed Sale |
85.42 |
10,111 |
863,637 |
0 |
| Kordasiewicz Holly B. | Officer |
Jul 07 '26 |
Proposed Sale |
84.30 |
1,287 |
108,494 |
0 |
| BENNETT C FRANK | Officer |
Jul 07 '26 |
Proposed Sale |
84.95 |
67,386 |
5,724,724 |
0 |
| BENNETT C FRANK | EVP, Chief Scientific Officer |
Jul 07 '26 |
Sale |
85.46 |
15,000 |
1,281,930 |
0 |
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):